Mineralys Therapeutics, Inc. [Rocket]

Overview

Mineralys Therapeutics, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
08/21/2023	4	Congleton Jon (CEO) has filed a Form 4 on Mineralys Therapeutics, Inc.
08/11/2023	4	Rodman David Malcom (Chief Medical Officer) has filed a Form 4 on Mineralys Therapeutics, Inc.
08/11/2023	4	Congleton Jon (CEO) has filed a Form 4 on Mineralys Therapeutics, Inc.
08/11/2023	144	Form 144 - Report of proposed sale of securities:
08/10/2023	144	Form 144 - Report of proposed sale of securities:
08/07/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/07/2023	8-K	Quarterly results

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21
Revenues	0.0	0.0
Cost of goods sold	0.0	0.0
Gross profit	0.0	0.0
Research and development	26.3	16.3
General and administrative	5.2	2.4
EBIT	31.5	18.7
Pre-tax income	29.8	19.4
Income taxes	0.0	0.0
Tax rate	0.0%	0.0%
Net income	29.8	19.4


EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy